ARA-290 12 mg

$70.00

Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food, or cosmetic.

 

ARA-290 Structure
Sequence: ZEQLERALNSS
Molecular Formula: C51H84N16021
Molecular Weight: 1257.3 g/mol
PubChem CID: 91810664
CAS No: 1208243-50-8
Synonyms: cibinetide, PH-BSP

Description

ARA-290, a small peptide derived from the helix beta domain of erythropoietin (EPO), possesses diverse therapeutic properties separate from its conventional role in stimulating red blood cell production in the bone marrow. EPO, a glycoprotein primarily synthesized in the kidney, demonstrates a range of actions including fostering blood vessel growth, supporting cell survival, influencing blood pressure, and providing neuroprotective effects in diabetic neuropathy. ARA-290 specifically delivers the neuroprotective and pain-relieving benefits associated with EPO while abstaining from the stimulation of red blood cell production[1].

Having successfully concluded phase II trials, ARA-290 is poised to progress into phase III trials, targeting various applications in diabetes and autoimmune sarcoidosis. Presently, the peptide garners significant attention for its efficacy in managing neuropathic pain. Additionally, ongoing research explores its potential as a catalyst for wound repair in chronic diabetes, an immune-modulating agent, and a plausible treatment option for systemic lupus erythematosus (lupus or SLE).

Check these out, you’ll love them!

0